Bank of Nova Scotia
NBIX icon

Bank of Nova Scotia’s Neurocrine Biosciences NBIX Stock Holding History

Bank of Nova Scotia’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$981K Sell
5,822
-1,277
-18% -$189K ﹤0.01% 876
2026
Q1 		$935K Sell
7,099
-433
-6% -$57.5K ﹤0.01% 839
2025
Q4 		$1.07M Buy
7,532
+1,166
+18% +$169K ﹤0.01% 880
2025
Q3 		$894K Buy
6,366
+1,131
+22% +$153K ﹤0.01% 810
2025
Q2 		$658K Buy
5,235
+1,067
+26% +$122K ﹤0.01% 822
2025
Q1 		$461K Buy
4,168
+81
+2% +$10.3K ﹤0.01% 824
2024
Q4 		$558K Sell
4,087
-790
-16% -$97.7K ﹤0.01% 841
2024
Q3 		$562K Sell
4,877
-9,883
-67% -$1.35M ﹤0.01% 823
2024
Q2 		$2.03M Buy
14,760
+7,514
+104% +$1.03M ﹤0.01% 634
2024
Q1 		$999K Sell
7,246
-970
-12% -$132K ﹤0.01% 769
2023
Q4 		$1.08M Buy
8,216
+1,785
+28% +$205K ﹤0.01% 764
2023
Q3 		$723K Sell
6,431
-2,385
-27% -$251K ﹤0.01% 756
2023
Q2 		$831K Sell
8,816
-118,734
-93% -$11.6M ﹤0.01% 700
2023
Q1 		$12.9M Sell
127,550
-12,768
-9% -$1.33M 0.04% 244
2022
Q4 		$16.8M Sell
140,318
-114,985
-45% -$13.5M 0.04% 266
2022
Q3 		$27.1M Buy
255,303
+243,505
+2,064% +$24.7M 0.09% 186
2022
Q2 		$1.15M Sell
11,798
-487
-4% -$44.9K ﹤0.01% 820
2022
Q1 		$1.15M Buy
12,285
+5,502
+81% +$466K ﹤0.01% 899
2021
Q4 		$578K Buy
+6,783
New +$624K ﹤0.01% 1074
2021
Q1 		– Sell
-5,780
Closed -$554K – 1095
2020
Q4 		$554K Buy
5,780
+697
+14% +$67.3K ﹤0.01% 880
2020
Q3 		$489K Buy
5,083
+976
+24% +$113K ﹤0.01% 897
2020
Q2 		$501K Buy
+4,107
New +$454K ﹤0.01% 746
2019
Q1 		– Sell
-71,000
Closed -$5.07M – 904
2018
Q4 		$5.07M Buy
+71,000
New +$6.8M 0.02% 405
2017
Q4 		– Sell
-61,600
Closed -$3.77M – 954
2017
Q3 		$3.77M Buy
61,600
+21,400
+53% +$1.13M 0.02% 426
2017
Q2 		$1.85M Buy
+40,200
New +$1.95M 0.01% 651

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bank of Nova Scotia's NBIX Position: Q2 2026 in Review

Bank of Nova Scotia reduced its Neurocrine Biosciences (NBIX) stake by 18% in Q2 2026, selling an estimated $189K and leaving 5,822 shares worth $981K. The position accounts for ﹤0.01% of the portfolio, ranked #876.

Bank of Nova Scotia first reported a position in NBIX in Q2 2017 and has held it in 25 quarters since. The position peaked at $27.1M in Q3 2022. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Bank of Nova Scotia held 5,822 shares of Neurocrine Biosciences worth $981K as of Q2 2026.
  • Bank of Nova Scotia sold 1,277 Neurocrine Biosciences shares in Q2 2026, an estimated $189K.
  • Neurocrine Biosciences made up ﹤0.01% of Bank of Nova Scotia's portfolio in Q2 2026, its #876 holding.
  • Bank of Nova Scotia first reported a position in Neurocrine Biosciences in Q2 2017 and has held it in 25 quarters since.
  • Bank of Nova Scotia's Neurocrine Biosciences position peaked at $27.1M in Q3 2022.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Bank of Nova Scotia's 13F filing for Q2 2026, filed 12 Aug 2026.